25 March 2021
Our partners AstraZeneca have today announced the high-level results from the primary analysis of their Phase III trial of the ChAdOx1 nCoV-19 coronavirus vaccine in the US. They confirm that the vaccine efficacy is consistent with the interim analysis results announced on Monday 22 March 2021.
24 March 2021
The VALIDATE Network, a community of over 400 researchers based in more than 200 research institutions in 63 countries, will today launch the “BCG100 Programme” marking the centenary of the Bacille Calmette-Guérin Vaccine for tuberculosis. BCG100 officially launches with the ‘BCG Then and Now’ online lecture by Professor Helen McShane, VALIDATE Network Director and Jenner Investigator and Professor Paul Fine, London School of Hygiene and Tropical Medicine. Taking place at 6pm GMT, 24 March 2021, the talk will cover the initial development of the vaccine, moving through to the modern-day challenges in the fight against TB and the future challenges researchers face in replacing the enduring BCG vaccine.
22 March 2021
A Phase III study of the Oxford-AstraZeneca coronavirus vaccine conducted by AstraZeneca plc in the USA, Chile and Peru has shown that vaccine is safe and highly effective, adding to previous trial data from the United Kingdom, Brazil and South Africa, as well as real-world impact data from the United Kingdom.
18 March 2021
Scientists at the University of Oxford have released pre-print data measuring the level of antibodies that can neutralise – or stop infection from – variants that are circulating in South Africa, Brazil and elsewhere. These data suggest that natural- and vaccine-induced antibodies can still neutralise these variants, but at lower levels. Importantly, the P1 ‘Brazilian’ strain may be less resistant to these antibodies than first feared.
Monday, 17 May 2021, 1pm to 2pm
Monday, 14 June 2021, 2pm to 3pm
Monday, 05 July 2021, 2pm to 3pm
During the COVID-19 pandemic, the Jenner Institute is taking measures to prevent the spread of the disease. Departments are instructed by the University’s Registrar to continue to work from home where possible, and manage the return to on site working, based on the University guidelines for risk assessments and work prioritisation. This is to restrict contact between individuals as far as possible. The University remains open and operating as far as possible with the following restrictions:
- No public access to the University.
- On-site activity permitted where it cannot be undertaken remotely, driven by safety, capacity and other factors such as schools reopening/other changes in government guidelines.
- Teaching and assessment are undertaken remotely where possible and, depending on government guidelines, gatherings of staff and students only permitted where essential for teaching and assessment to take place.
UPDATE ON COVID-19 VACCINE Trial
For all information and enquiries regarding the COVID-19 vaccine trial, please visit: https://covid19vaccinetrial.web.ox.ac.uk/.
Emary KRW. et al, (2021), Lancet, 397, 1351 - 1362
Addy JWG. et al, (2021), Wellcome Open Research, 6, 79 - 79
SUPPORT OXFORD’S COVID-19 VACCINE RESEARCH
Funding for Oxford’s COVID-19 vaccine research requires unprecedented speed, scope and ambition. Support from Government, corporations, trusts and foundations will be crucial to the development of a vaccine to combat the new virus. Alongside those traditional sources of funding, philanthropic donations of any size will have real and rapid impact, allowing us to accelerate this time-critical research, and ensure that Oxford’s vaccine solution will be as effective and swift as possible.
If you are interested in supporting this effort, please make a gift here.